EGFR and non-small cell lung carcinoma: In this phase 3 randomized clinical trial, our results revealed that gefitinib plus chemotherapy significantly improved intracranial PFS, PFS, and OS in patients with untreated NSCLC EGFR mutation and asymptomatic brain metastases.